CD19 and lymphoma: Recently, allogeneic KIR mismatched, anti-CD19 CAR NK-cells derived from cord blood have shown to be an effective strategy to treat lymphoma patients [109]; however, there is currently only one running clinical trial investigating CAR NK-cells in MM (NCT03940833) [110].